Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ$1.215+0.02 (1.67%)
Market Cap
$3.22M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
681 of 924
Rank in Industry
388 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
LIXT Insider Trading Activity
LIXT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically …
Insider Activity of Lixte Biotechnology Holdings, Inc.
Over the last 12 months, insiders at Lixte Biotechnology Holdings, Inc. have bought $0 and sold $0 worth of Lixte Biotechnology Holdings, Inc. stock.
On average, over the past 5 years, insiders at Lixte Biotechnology Holdings, Inc. have bought $538,785 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,527 shares for transaction amount of $13,873 was made by Bernards Rene (director) on 2023‑10‑03.
List of Insider Buy and Sell Transactions, Lixte Biotechnology Holdings, Inc.
| 2023-10-03 | Bernards Rene | director | 5,527 0.2398% | $2.51 | $13,873 | -13.69% | ||
| 2023-10-03 | van der Baan Bastiaan Jeroen | President and CEO | 10,000 0.484% | $2.80 | $28,000 | -13.69% | ||
| 2023-10-02 | Bernards Rene | director | 4,473 0.1771% | $2.29 | $10,243 | -4.05% | ||
| 2022-12-30 | van der Baan Bastiaan Jeroen | director | 10,000 0.0609% | $0.49 | $4,900 | +1.86% | ||
| 2022-12-15 | Bernards Rene | director | 15,000 0.0893% | $0.51 | $7,650 | -3.70% | ||
| 2022-12-12 | Bernards Rene | director | 10,000 0.0632% | $0.61 | $6,100 | -14.75% | ||
| 2022-12-09 | FORMAN ERIC | Vice President and COO | 1,112 0.0071% | $0.63 | $701 | -15.89% | ||
| 2022-11-22 | FORMAN ERIC | Vice President and COO | 2,484 0.0154% | $0.56 | $1,391 | -3.68% | ||
| 2022-11-21 | FORMAN ERIC | Vice President and COO | 1,457 0.0092% | $0.56 | $816 | -1.79% | ||
| 2022-11-21 | Brown Regina | director | 5,000 0.0325% | $0.58 | $2,876 | -1.79% | ||
| 2022-11-18 | FORMAN ERIC | Vice President and COO | 16,207 0.0994% | $0.56 | $9,125 | -5.17% | ||
| 2022-11-17 | FORMAN ERIC | Vice President and COO | 4,852 0.0307% | $0.54 | $2,619 | +1.85% | ||
| 2022-11-14 | Bernards Rene | director | 52,500 0.3141% | $0.53 | $27,825 | -1.79% | ||
| 2020-11-30 | Kovach John S | President and CEO | 21,100 0.0394% | $4.75 | $100,225 | -24.01% | ||
| 2020-11-30 | GREENBERG ROBERT | 10 percent owner | 52,632 0.0984% | $4.75 | $250,002 | -24.01% | ||
| 2020-11-30 | Schwartzberg Gil | 10 percent owner | 105,264 0.1968% | $4.75 | $500,004 | -24.01% | ||
| 2020-11-30 | Yen Yun | director | 52,632 0.0984% | $4.75 | $250,002 | -24.01% | ||
| 2020-11-30 | Forman Stephen J. | director | 21,053 0.0394% | $4.75 | $100,002 | -24.01% | ||
| 2020-11-30 | Palmedo Philip F | director | 21,053 0.0394% | $4.75 | $100,002 | -24.01% | ||
| 2020-11-30 | Ho Hung Tak | 10 percent owner | 42,105 0.0787% | $4.75 | $199,999 | -24.01% |
Total: 30
Insider Historical Profitability
<0.0001%
| Riggs Arthur | 10 percent owner | 6110000 227.6394% | $7.33M | 3 | 0 | |
| Kovach John S | President and CEO | 1540183 57.3824% | $1.85M | 1 | 0 | <0.0001% |
| GREENBERG ROBERT | 10 percent owner | 994299 37.0445% | $1.19M | 1 | 0 | <0.0001% |
| Schwartzberg Gil | 10 percent owner | 247775 9.2313% | $297,330.00 | 3 | 0 | <0.0001% |
| Yen Yun | director | 52632 1.9609% | $63,158.40 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $3.75M | |
$1,138,733 | 28 | -4.94% | $2.7M | |
$63,749,694 | 24 | -12.24% | $2.37M | |
Lixte Biotechnology Holdings, Inc. (LIXT) | $1,616,354 | 20 | -12.22% | $3.22M |
$960,082 | 17 | -6.29% | $3.61M |
LIXT Institutional Investors: Active Positions
| Increased Positions | 4 | +44.44% | 116,168 | +53.9% |
| Decreased Positions | 3 | -33.33% | 34,143 | -15.84% |
| New Positions | 3 | New | 114,579 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 10 | +11.11% | 297,557 | +38.06% |
LIXT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Tiaa Trust, National Association | $132.00 | 3.39% | 101,834 | +101,834 | New | 2024-12-31 |
| Hightower Advisors, Llc | $129.00 | 3.31% | 99,432 | 0 | 0% | 2024-12-31 |
| Fny Investment Advisers, Llc | $51.00 | 1.31% | 39,219 | -32,419 | -45.25% | 2024-12-31 |
| Ethos Financial Group, Llc | $32.00 | 0.83% | 24,808 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $22.00 | 0.56% | 16,866 | -295 | -1.72% | 2024-12-31 |
| Atlas Legacy Advisors, Llc | $17.00 | 0.42% | 12,707 | +12,707 | New | 2024-12-31 |
| Ubs Group Ag | $3.00 | 0.07% | 1,956 | +1,589 | +432.97% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 681 | -1,429 | -67.72% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 38 | +38 | New | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 16 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.